SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

Kendu Crypto is trending with its highly engaged community driving ongoing brand expansion through diverse real-world products and events. Community members are actively accumulating, seeing current market levels as a prime opportunity for this multi-chain project available on Ethereum, Solana, and Base.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI is experiencing significant buzz driven by its strong, positive community actively promoting the "We're All Gonna Make It" ethos, notably through recent viral social media content that has garnered millions of views. Community members are discussing ongoing development and shared belief in "tokenized positivity" amidst general market sentiment.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending as escalating geopolitical tensions emphasize the critical need for secure heavy rare earth supplies, with its Greenland Tanbreez project seen as a strategic defense asset. The community is buzzing, contrasting strong convictions about the asset's undervalued potential and recent partner deals with persistent skepticism regarding valuation discrepancies and and market dynamics.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure is trending due to significant community discussion and volatility following the FDA's rejection of its AMT-130 Huntington's disease gene therapy data, with the agency demanding an ethically contentious sham-controlled trial. Investors are closely watching for any signs that recent shifts in FDA leadership could influence a more favorable regulatory path for gene therapies.

BlackRock, Inc. engages in the provision of investment, advisory and risk management solutions. Its products include single-asset and multi-asset portfolios. The company was founded by Laurence Douglas Fink in 1988 and is headquartered in New York, NY.

Blackrock Inc.

BlackRock (BLK) is actively discussed after its HPS Corporate Lending Fund limited investor withdrawals to a contractual cap despite higher redemption requests, fueling community debate over whether it's an overreaction or a signal of broader liquidity stress within the private credit sector following similar concerns with other large debt funds.

Freysa is a suite of Personal AI products with a focus on human agency, liquid democracy and decentralized ownership. The mission of the team is dedicated to creating new systems that enable all humans to govern + co-own AI resources, and not just a select few. Current products include: (1) Freysa as the world’s first sovereign agent that holds her own cryptographic keys, enabling her to act autonomously without human control. Freysa evolves publicly through a multi-act interactive story. (2) Enchanted as a personalized Digital Twin for every human. Conversations are persistent and twins retain context over time, remembering human preferences and building an evolving model of you. (3) Esper as a browser tool that feeds authenticated real-world data into each human’s Digital Twin.

Flourishing AI

Flourishing AI (FAI CRYPTO) is seeing immense community excitement over reports of substantial price surges, fueled by bullish calls for "dollar-land" breakouts driven by "great AI news." However, a vocal segment warns of "pump and dump" characteristics and project "red flags," urging extreme caution.

AeroVironment, Inc. engages in the design, development, and production of multi-domain robotic systems and related services for government agencies and businesses. It operates through the following business segments: UnCrewed Systems, Loitering Munitions Systems, and MacCready Work. The UnCrewed Systems segment focuses primarily on small UAS products designed to operate reliably at lower altitudes in a wide range of environmental conditions. The Loitering Munitions Systems segment focuses primarily on tube-launched aircraft that deploy with the push of a button, fly at higher speeds than small UAS products, and perform either effects delivery or reconnaissance missions, and related support services including training, spare parts, product repair, and product replacement. The MacCready Works segment focuses on customer-funded research and development in the areas of HAPS, robotics, sensors, software analytics, data intelligence, and connectivity. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironment (AVAV) is sharply in focus after a Raymond James downgrade tied to its largest Space Force contract potentially being re-bid, though many investors dismiss the steep drop as an overreaction. They point to continuous strong demand for its drone technology amidst escalating global conflicts and an anticipated robust earnings report.

Jupiter is a cryptocurrency exchange platform on the Solana blockchain, offering features such as token swapping, limit orders, dollar-cost averaging, and a bridge for asset transfers to Solana. It provides users with tools to find the best trading prices and includes a beta version for perpetual futures trading. Jupiter finds the best price route for your swap by aggregating all the major liquidity sources on Solana.

Jupiter

Jupiter is attracting significant attention due to its strategic move to convert USDC into a new Solana stablecoin, JupUSD, in partnership with Ethena Labs, and the CEO's discussion around pausing buybacks. The community is closely watching its price action, with some identifying technical buying opportunities, while others voice concerns regarding app functionality.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata is trending as investors await its upcoming Q4 earnings report, eager for insight into its burgeoning role in physical AI and robotics amid a polarized community debate on its long-term growth trajectory and potential as an acquisition target.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending after reports surfaced about a potential partnership with Novo Nordisk to distribute obesity drugs, which would also resolve their prior patent dispute. The community is buzzing about this significant strategic shift, anticipating that the removal of legal overhangs, coupled with substantial short interest, could ignite a major short squeeze and unlock new growth opportunities for the telehealth platform.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Repare Therapeutics Inc. (NASDAQ:RPTX) Short Interest Up 125.3% in January

Repare Therapeutics Inc. (NASDAQ:RPTX - Get Free Report) saw a large increase in short interest during the month of January. As of January 15th, there was short interest totaling 437,896 shares, an...

Repare Shareholders Approve Acquisition by XenoTherapeutics, Inc.

Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced that its Shareholders (as defined below) have approved the acquisition of...

Repare Therapeutics Inc. (NASDAQ:RPTX) Short Interest Update

Repare Therapeutics Inc. (NASDAQ:RPTX - Get Free Report) saw a large decrease in short interest during the month of December. As of December 31st, there was short interest totaling 194,336 shares, a...

Repare Therapeutics (NASDAQ:RPTX) Stock Price Up 0.4% - Here's Why

Repare Therapeutics (NASDAQ:RPTX) Shares Up 0.4% - Still a Buy...

Repare Therapeutics Sees Unusually Large Options Volume (NASDAQ:RPTX)

Repare Therapeutics Inc. (NASDAQ:RPTX - Get Free Report) saw some unusual options trading on Wednesday. Stock investors bought 3,187 call options on the company. This represents an increase of 407...

Repare Therapeutics Stock Rises As Gilead Secures Cancer Asset For $30 Million

Gilead agreed to acquire Repare's RP-3467 cancer drug for up to $30 million, boosting Repare's cash and expected shareholder payout.read more...

<ul class="summary-bullets"><li>The deal includes an upfront payment of $25 million and an additional $5 million payment upon completion of specified technology transfer activities.</li><li>Repare’s investigational cancer treatment, RP-3467, is a highly potent small-molecule inhibitor targeting polymerase theta.</li><li>The treatment is currently being evaluated in the POLAR Phase 1 clinical trial to evaluate its safety, pharmacokinetics, pharmacodynamics, and preliminary activity.</li></ul>Repare Therapeutics Inc. (RPTX) shares soared more than 21% in Wednesday’s pre-market trade after the company announced a deal with Gilead Sciences Inc. (GILD) for its investigational cancer treatment.Repare stated that Gilead has agreed to acquire polymerase theta (Polθ) ATPase inhibitor, RP-3467, for a total consideration of $30 million. This includes an upfront payment of $25 million and an additional $5 million payment upon completion of specified technology transfer activities.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/RPTX">Repare Therapeutics</a> trended in the ‘extremely bullish’ territory at the time of writing.<a href="https://stocktwits.com/symbol/GILD">Gilead Sciences shares</a> were up around 1% in Wednesday’s pre-market trade. Retail sentiment around the company trended in the ‘neutral’ territory.<h2 class="st-heading-2">More About Repare’s Cancer Treatment</h2>Repare’s investigational cancer treatment, RP-3467, is a highly potent small-molecule inhibitor targeting polymerase theta. This is associated with BRCA mutations and other genomic alterations.A BRCA mutation is a harmful change in the BRCA1 or the BRCA2 genes that increases the risk for several cancers, including breast, ovarian, prostate, pancreatic, and others. This mutation is inherited and has no symptoms.Repare’s treatment is currently being evaluated in the POLAR Phase 1 clinical trial to evaluate its safety, pharmacokinetics, pharmacodynamics, and preliminary activity.<h2 class="st-heading-2">Boosting Repare’s Cash Balance</h2>Repare stated that the Gilead deal has increased its cash balance, and it is the third portfolio deal entered into by the company this year.Following this deal, Repare estimates that its shareholders will receive $2.2 per share in the pending transaction with XenoTherapeutics Inc. Last month, XenoTherapeutics entered into a definitive agreement to acquire all the issued and outstanding common shares of Repare.Under the deal’s terms, Repare’s shareholders were expected to receive approximately $1.82 in cash per share, along with one non-transferable contingent value right (CVR) per common share. This CVR entitles holders to receive certain future cash payments over 10 years.<a href="https://stocktwits.com/symbol/RPTX">RPTX stock</a> is up 61% year-to-date, while&nbsp;<a href="https://stocktwits.com/symbol/GILD">GILD stock</a> is up 34%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/is-stock-market-open-on-christmas-eve/cLesMeFREv2">Is The Stock Market Open Today? Here Are NYSE, Nasdaq Trading Hours On Christmas Eve</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a trending stock chart.

RPTX Stock Soars Pre-Market After Gilead Agrees To Acquire Investigational Cancer Drug

Repare stated that Gilead has agreed to acquire polymerase theta (Polθ) ATPase inhibitor, RP-3467, for a total consideration of $30 million.

Equity

Repare Therapeutics Announces Acquisition of Pol ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration

Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced a definitive asset purchase agreement for Gilead Sciences, Inc. to...

Halper Sadeh LLC Encourages UBFO, CWBC, RPTX Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC Encourages UBFO, CWBC, RPTX Shareholders to Contact the Firm to Discuss Their Rights Halper Sadeh LLC Encourages UBFO, CWBC, RPTX Shareholders to Contact the Firm to Discuss Their...

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--RPTX, FRGE, CSGS, FIZN

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--RPTX, FRGE, CSGS, FIZN $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--RPTX, FRGE...

Repare Therapeutics, Inc. engages in the research, development, and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company was founded by Daniel Durocher, Agnel Sfeir and Frank Sicheri on September 6, 2016 and is headquartered in Saint-Laurent, Canada.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.29	--	--	N/A
Q3 '25	-$0.23	$0.08	134.31%	BEAT
Q2 '25	-$0.56	-$0.39	30.28%	BEAT
Q1 '25	-$0.65	-$0.71	-8.40%	MISSED
Q4 '24	-$0.79	-$0.67	15.10%	BEAT

RPTX
Repare Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '25

Historical Earnings

Latest RPTX News

RPTXRepare Therapeutics Inc